Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery by Savulich, G. et al.
OPEN
ORIGINAL ARTICLE
Effects of naltrexone are inﬂuenced by childhood adversity
during negative emotional processing in addiction recovery
G Savulich1,2, R Riccelli2,3, L Passamonti4, M Correia5, JFW Deakin6, R Elliott6, RSA Flechais7, AR Lingford-Hughes7, J McGonigle7,
A Murphy6, DJ Nutt7, C Orban7, LM Paterson7, LJ Reed7, DG Smith1,2, J Suckling1,2, R Tait1,2, EM Taylor6, BJ Sahakian1,2, TW Robbins2,8,
KD Ersche1,2 and ICCAM Platform
Naltrexone is an opioid receptor antagonist used in the management of alcohol dependence. Although the endogenous opioid
system has been implicated in emotion regulation, the effects of mu-opioid receptor blockade on brain systems underlying
negative emotional processing are not clear in addiction. Individuals meeting criteria for alcohol dependence alone (n= 18, alcohol)
and in combination with cocaine and/or opioid dependence (n= 21, alcohol/drugs) and healthy individuals without a history of
alcohol or drug dependence (n= 21) were recruited. Participants were alcohol and drug abstinent before entered into this
double-blind, placebo-controlled, randomized, crossover study. Functional magnetic resonance imaging was used to investigate
brain response while viewing aversive and neutral images relative to baseline on 50 mg of naltrexone and placebo. We found that
naltrexone modulated task-related activation in the medial prefrontal cortex and functional connectivity between the anterior
cingulate cortex and the hippocampus as a function of childhood adversity (for aversive versus neutral images) in all groups.
Furthermore, there was a group-by-treatment-by-condition interaction in the right amygdala, which was mainly driven by a
normalization of response for aversive relative to neutral images under naltrexone in the alcohol/drugs group. We conclude that
early childhood adversity is one environmental factor that inﬂuences pharmacological response to naltrexone. Pharmacotherapy
with naltrexone may also have some ameliorative effects on negative emotional processing in combined alcohol and drug
dependence, possibly due to alterations in endogenous opioid transmission or the kappa-opioid receptor antagonist actions of
naltrexone.
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INTRODUCTION
Emotions have a critical role in the development, maintenance
and successful treatment of addiction.1–3 Suppression of negative
affective states such as anxiety and withdrawal symptoms is one
motivational pathway to support the consumption of alcohol.4,5
As negatively reinforced drinking becomes more pronounced,
negative affective states increase, thereby escalating alcohol
intake and raising vulnerability to relapse after treatment.6,7
Negative reinforcement is driven by activation of stress-induced
neurocircuitry in what is widely referred to as the ‘dark side’ view
of addiction.8,9 Negative emotion is thus a key affective process
that could be targeted by treatment interventions for addiction.
Functional abnormalities during negative emotional processing
have been found in limbic and cortical networks in substance
dependence.1 Threat-related reactivity of the amygdala, for example,
is strongly associated with negatively reinforced problem
drinking.10 Connectivity between the amygdala and the hippo-
campus is associated with maladaptive emotional processing,11
and alterations in hippocampal network activation and connec-
tivity have been shown to predict relapse.12 The prefrontal cortex
has extensive connections with subcortical structures that
regulate emotional processing, including the amygdala.13 Alcohol
and drug exposure impairs emotion regulation in this region, with
interconnected medial and cingulate networks showing enhanced
reactivity to arousing stimuli and reduced capacity to suppress
negative affect.14 The medial prefrontal cortex (mPFC) and
anterior cingulate cortex (ACC) also act to appraise and regulate
negative emotions.15 These cortical areas over-activate in
response to substance-related and naturally evocative stimuli16
and, together with limbic regions associated with impaired
emotional processing in addiction, are candidate loci for
pharmacological intervention.
Naltrexone is one pharmacotherapy used in the management of
alcohol dependence that works by modulating opioid control of
dopaminergic cell ﬁring in the ventral tegmental area, thus
preventing an increase in dopaminergic activity.17 The endogen-
ous opioid system has been implicated in emotion regulation.18
There is some evidence of naltrexone dampening responses to
negative emotional stimuli in healthy adults,19 although this likely
reﬂects stress-reducing effects of the potent kappa-opioid
receptor (KOR) antagonist actions of naltrexone. mu-opioid
receptor (MOR) antagonism is known to precipitate withdrawal
symptoms in humans with current20 and previous21 opiate use.
MOR antagonism also precipitates aversive consequences of
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withdrawal from chronic opioid exposure in animals.22,23 Naltrex-
one increases negative emotions in response to stress- and
drug-related images in individuals with opioid dependence24 and
increases anxiety in response to drug-related ﬁlms in individuals
with alcohol and cocaine dependence.25 However, the efﬁcacy of
naltrexone treatment has been shown to be associated with
greater naltrexone-induced aversion26 (that is, the more negative
the aversive stimulus, the greater the treatment response). This
may be due, in part, by activation of the hypothalamic–pituitary–
adrenal (HPA) axis associated with all substances of abuse
potential. Speciﬁcally, naltrexone-induced adrenocorticotropic
hormone and cortisol levels are thought to reduce craving in
individuals with alcohol dependence.27 Exposure to psychological
trauma, another form of aversion, is also known to contribute to
individual treatment responses to naltrexone.28 This is consistent
with preclinical evidence showing that early environmental
adversity is associated with better treatment effects of
naltrexone,29 suggesting that adversity experienced in early
stages of development upregulates endogenous opioid function.
Childhood adversity has long been known to be common in
substance use disorders, with at least two-thirds of alcohol- or
drug-dependent adults reporting a history of physical, sexual or
emotional abuse.30 Childhood adversity leads to more illicit
substance use and increases the risk of dependence in
adulthood.31–33 Combined alcohol and drug dependence is
particularly harmful, as individuals dependent on both consume
more units of alcohol and have greater incidence and severity of
psychiatric illness than individuals dependent on alcohol alone.34
The heterogeneity of alcohol use disorders, including concurrent
non-alcohol drug use, necessitates development of more tailored
treatment approaches.35,36 However, patients are typically cate-
gorized according to their primary dependency or by the drug for
which they seek treatment.37 Personalized assessment and
specialized treatments addressing the effects of combined alcohol
and drug-taking behavior are often omitted, thus reducing the
potential for more successful recovery.6
We used functional magnetic resonance imaging (fMRI) to
investigate brain response to aversive and neutral images. We
sought to determine the effects of naltrexone at standard dose
(50 mg) during negative emotional processing between groups
dependent on alcohol alone, dependent on alcohol and drugs
(both in abstinence) and healthy control volunteers. On the basis
of previous research showing altered activation in limbic and
cortical networks during negative emotional processing in
substance-dependent individuals,1,10–15 including the processing
of evocative16 and negative emotional images,38,39 we hypo-
thesized that the dependent groups would show increased
activation in the amygdala, the mPFC and the hippocampus in
response to aversive images. In light of preclinical evidence,29 we
further hypothesized that these effects would be modulated by
naltrexone depending on the degree of childhood adversity
experienced.
MATERIALS AND METHODS
Participants
This was a double-blind, placebo-controlled, randomized, crossover study
involving three sites (Imperial College London, University of Cambridge,
University of Manchester; ICCAM). Full details of the ICCAM platform are
reported elsewhere.40–42 Brieﬂy, inclusion criteria were ﬂuency in English;
age 20–64; meeting DSM-IV criteria43 for alcohol, cocaine, amphetamine or
opiate dependence; and abstinence from alcohol or drugs for at least
4 weeks prior to the experimental medicine sessions. Control participants
did not meet DSM-IV criteria for any disorder. Exclusion criteria for all
participants were use of medication that could not be paused for the study
duration; current primary Axis I or neurological diagnosis; current or past
psychiatric history (excluding lifetime or secondary history of anxiety or
depression); and MRI contraindications. All participants screened negative
(using urine samples) for amphetamines, barbiturates, cocaine, opiates,
cannabinoids and benzodiazepines.
Here, we compared the effects of naltrexone between individuals who
were only dependent on alcohol from individuals who in addition to
alcohol were also dependent on cocaine and/or opiates. This distinction
was made due to evidence showing that individuals dependent on alcohol
and drugs have more severe psychopathology,34 and differences in brain
function44 and structure45 compared with individuals dependent on
alcohol alone. Control participants with a history of heavy alcohol or drug
use were also excluded due to known associated functional and structural
abnormalities.46 Heavy alcohol use was deﬁned as a score higher than
eight on the Alcohol Use Disorders Identiﬁcation Test (AUDIT).47 Heavy
drug use was deﬁned by clinicians of the ICCAM team using the following
criteria: more than 300 pills (lifetime) for MDMA; daily/almost daily THC use
for more than one year and more than 2 spliffs; and more than once a
week for more than six months and more than 1 g for amphetamines. On
the basis of these criteria, patients with drug dependence but without
alcohol dependence (n= 11) and control participants with a history of
heavy alcohol or drug use (n= 9) were excluded.
The ﬁnal alcohol group (alcohol) comprised 18 individuals meeting
criteria for alcohol dependence only. The alcohol and drugs group
(alcohol/drugs) comprised 21 individuals meeting criteria for alcohol
dependence and the following drug dependencies: cocaine (42.9%);
cocaine and opiates (47.6%); amphetamines (4.8%); and opiates (4.8%). The
control group comprised 21 individuals without a history of alcohol or drug
dependence.
Baseline assessment
All participants completed the Wechsler Test of Adult Reading (WTAR)48 to
measure verbal intelligence and control volunteers also completed the
AUDIT to screen for harmful drinking patterns. To investigate the effects of
individual variations of perceived stress and adverse childhood experi-
ences on emotional processing, participants completed the Perceived
Stress Scale (PSS-14)49 and the Childhood Trauma Questionnaire (CTQ).50
For the PSS-14, we used the total score and for the CTQ we calculated an
abuse composite score from three abuse subscales, that is, physical, sexual
and emotional abuse.51 In light of prior research suggesting the effects of
naltrexone might be modulated by variations in locus of control beliefs,52
participants completed Rotter’s locus of control scale53 and a drug-related
version.51
Procedure
This study received ethical approval from the West London and Gene
Therapy Advisory Committee National Research Ethics Service committee
(11/H0707/9). Participants provided consent, basic demographic informa-
tion and baseline assessment measures. For the experimental medicine
sessions, participants completed a urine screen and alcohol breath and
pregnancy tests. Participants screening negative were dosed 2 h prior to
the MRI scan. The experimental medicine sessions consisted of adminis-
tering placebo or 50 mg of naltrexone in a counterbalanced order. The
Beck Depression Inventory (BDI-II)54 and the Spielberger-State Anxiety
Inventory (STAI)55 were administered to evaluate current mood on the day
of testing. Smoking was permitted up to 1 h before scanning; caffeine was
only permitted in the morning. Participants were given a snack on arrival
but subsequent food intake was restricted to ensure full drug absorption.
The experimental medicine sessions were separated by at least 1 week.
Evocative images task
The evocative images task probes negative arousal to aversive stimuli.40
Aversive images of threat or injury were contrasted with neutral images of
human or inanimate objects selected from the International Affective
Picture System (IAPS: https://csea.phhp.uﬂ.edu/media/iapsmessage.html).
Any images with alcohol or drugs in them were not included. Similar tasks
have been used to demonstrate functional activation in alcohol- and drug-
dependent groups in response to negative IAPS images.38,39 A total of 240
images (120 aversive, 120 neutral) were presented in a block design
consisting of two runs. Each run contained eight blocks of six images
presented for 5 s each, followed by a 400 ms inter-stimulus interval that
consisted of a ﬁxation cross. Participants were given the implicit task to
press a response button when the next image appeared on the screen.
Images were counterbalanced for valence and arousal between sessions
and between blocks and were presented in a pseudorandomized order,
with a neutral image always presented ﬁrst. Each block was separated by a
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15 s rest period to prevent habituation effects. Response latency (in ms)
was recorded for each participant in response to all images presented.
Statistical analysis
Demographic, baseline assessment and behavioral measures. Demographic
and baseline assessment measures were analyzed using univariate analysis
of variance (ANOVAs) for continuous variables and chi-square for
categorical variables. Post-hoc Tukey tests were used to identify pairwise
differences for continuous variables. Mean response latencies during
emotional processing were square-root transformed to stabilize variances
relative to the mean (untransformed scores presented in Table 1).
Repeated-measures ANOVAs were used with the two within-subject
factors condition (neutral, aversive) and treatment (placebo, naltrexone)
and the between-subject factor group (control, alcohol, alcohol/drugs) to
examine response latencies.
Repeated-measures ANOVAs were also used to evaluate changes in
affective states between the experimental medicine visits. To determine
the inﬂuence of naltrexone on task performance, we calculated a change
score for each individual by subtracting mean latencies from each
condition (aversive minus neutral) following placebo and naltrexone. We
then used Pearson’s r coefﬁcients to test for associations between change
scores and individual variations in affective states.
Neuroimaging data acquisition, processing and analysis. Volumetric MRI
data was acquired with 3 T systems at three sites (Imanova, London;
Wolfson Brain Imaging Centre, Cambridge; and the Translational
Imaging Unit, Manchester). London and Cambridge operated nominally
identical 3 T Siemens Tim Trio systems and Manchester operated a 3 T
Philips Achieva.
fMRI data were preprocessed using SPM8. Mean echo-planar imaging
(EPI) was ﬁrst computed for each participant and visually inspected in the
orbitofrontal cortex and temporal lobe to ensure that none showed
excessive signal dropout. All EPIs were then realigned to the ﬁrst scan by
rigid body transformations to correct for head movements. Next, EPIs were
normalized to the standard template in the Montreal Neurological Institute
(MNI) space using linear and nonlinear transformations and smoothed with
a Gaussian kernel of full width at half maximum of 8 mm. Realignment
parameters were then inspected for each subject to make sure that
movements of translation and rotation were o2 mm and 2°, respectively.
To identify signiﬁcant differences across groups in regional responses of
brain areas, a general linear model (GLM) was employed. Subject-speciﬁc
GLMs included three experimental factors (aversive images, neutral images
and ﬁxation cross) and six realignment parameters as effects of no interest
to account for residual motion-related variance. Low-frequency signal drift
was removed using a high-pass ﬁlter (cut-off 128 s). An autoregressive
modeling of temporal autocorrelations was applied. The following
contrasts were generated for the second-level analysis: (1) aversive images
versus neutral images, (2) aversive images versus ﬁxation cross and (3)
neutral images versus ﬁxation cross.
Group differences in brain responses were assessed via: (1) a full factorial
analysis for the contrast ‘aversive versus neutral’ including three groups
(control, alcohol, alcohol/drugs) and two pharmacological treatments
(placebo, naltrexone) as main factors and (2) a full factorial analysis
including three groups (control, alcohol, alcohol/drugs), two pharmacolo-
gical treatments (placebo, naltrexone) and two task conditions (aversive
images versus ﬁxation cross, neutral images versus ﬁxation cross) as main
factors. For each model, SPM-F-maps assessing the main effect of group,
the main effect of treatment, the group-by-treatment interaction and the
group-by-treatment-by-condition interaction were generated, respectively.
An additional covariate of site was added to remove the effect of the
different scan sites. In the ﬁrst model, we also included the abuse
composite score as a covariate-of-interest to test for associations between
brain response and childhood adversity as a function of pharmacological
treatment.
To threshold the second-level maps, we used a priori regions of interest
(ROIs) based on a functional deﬁnition of the brain regions as previously
recommended (Po0.05, family-wise error (FWE) correction for multiple
comparisons after a small volume correction).56–59 This commonly
employed statistical procedure not only ensures a robust protection
against type I errors but also prevents false negative results.
Here, the following anatomical ROIs were selected because of their
functional role in negative emotional processing in substance use
disorders:1,10–16,38,39 the amygdala, the mPFC and the hippocampus. Each
ROI was deﬁned using a sphere centered on MNI coordinates obtained
from previous studies.60,61 Speciﬁcally, a sphere with a radius of 5 mm was
centered on the right amygdala (x,y,z: 25,− 3,− 27), a sphere with a radius
of 10 mm was centered on the right mPFC (x,y,z: 14,62,1) and a sphere with
a radius of 8 mm was centered on the right hippocampus (x,y,z:
29,− 14,− 14). The different size of the spheres was chosen to reﬂect the
actual size of the regions. Brain regions that were not predicted a priori but
met a threshold of Po0.05, whole-brain corrected, were also reported.
Functional connectivity: psycho-physiological interaction analyses. Psycho-
physiological interaction (PPI) represents the change in connectivity
between a seed region and the rest of the brain that is induced by a
speciﬁc psychological context. The ACC was chosen as a seed due to the
high density of MORs in this region that potentially reﬂects higher binding
potential associated with greater capacity to modulate negative emotional
processing.62 We sought to identify brain regions that had a differential
functional connectivity pattern with the seed region during the processing
of aversive versus neutral images. For each participant, a 15 mm sphere
was centered on the right anterior cingulate cortex (x,y,z: 6,60,4; extracted
from the ﬁrst model). The time series of the BOLD response for each
participant was then computed using the ﬁrst eigenvariate from all voxels’
time series in the sphere.
The BOLD time series for each individual was deconvolved to estimate a
neuronal time series for the source, using the PPIs deconvolution
parameter defaults in SPM8.63 The PPI regressor was calculated as the
element-by-element product of the seed neuronal time series and a vector
coding for the main effect of task (1 for aversive images, − 1 for neutral
images). This product was reconvolved by the canonical haemodynamic
response function. The statistical model also included the main effect of
the task convolved by the haemodynamic response function, the seed
neuronal time series and the six movement parameters as effects of no
interest.
Subject-speciﬁc PPI models were run, and contrast images were
generated such that the identiﬁed target regions were those that showed
a change in connectivity with the ACC during the processing of aversive
versus neutral images. Subject-speciﬁc PPI contrast images were entered
into second-level GLMs to assess if change in connectivity between the
ACC and other regions in the brain were associated with childhood
adversity as a function of pharmacological treatment. The same statistical
approaches previously described were employed to threshold the second-
level PPI maps.
RESULTS
Demographic information and baseline assessment
As shown in Table 2, the three groups did not differ with regard to
gender, age, verbal intelligence, handedness, smoking status and
Table 1. Evocative Images task mean group latencies (ms) and standard deviations in response to neutral and aversive images on placebo and
naltrexone
Condition Treatment Control group, n= 21 Alcohol group, n= 18 Alcohol/drugs group, n= 21
Neutral images Placebo 691.14 (±294.94) 862.17 (±291.95) 740.62 (±313.31)
Neutral images Naltrexone 671.14 (±237) 893.50 (±354.28) 724.29 (±219.06)
Aversive images Placebo 684.48 (±261.16) 945.94 (±368.01) 855.71 (±457.75)
Aversive images Naltrexone 689.76 (±238.30) 970.39 (±478.30) 806.71 (±382.78)
Means are untransformed scores.
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locus of control beliefs (all P’s40.05). However, signiﬁcant group
differences emerged with regard to stress sensitivity (F2,57 = 5.71,
P= 0.005) and childhood adversity (F2,57 = 6.63, P= 0.003), such
that the alcohol/drugs group reported signiﬁcantly higher
sensitivity to stress compared with the control group (Tukey’s
P= 0.004) and signiﬁcantly higher levels of childhood adversity
compared with the control (Tukey’s P= 0.005) and alcohol (Tukey’s
P= 0.012) groups.
The groups also differed with regard to affective states (BDI-II,
STAI-State) on the day of testing, as assessed prior to scanning on
placebo (F2,57 = 6.37, P= 0.003; F2,57 = 8.42, P= 0.001) and naltrex-
one (F2,57 = 5.04, P= 0.010; F2,57 = 3.93, P= 0.025). The alcohol/
drugs group scored signiﬁcantly higher than the control group on
total scores for both measures (both Tukey’s P= 0.002). However,
affective state did not signiﬁcantly ﬂuctuate between the two
experimental medicine sessions, as reﬂected by non-signiﬁcant
group-by-session interactions (BDI-II: F2,57 = .64, P= 0.534; STAI-
State: F2,57 = 2.13, P= 0.129), and the main effects of treatment
were not signiﬁcant for either measure (BDI-II: F1,57 = 1.41,
P= 0.240; STAI-State: F1,57 = 1.72, P= 0.194). Total scores of the
BDI-II and STAI-State did not correlate signiﬁcantly with behavioral
change scores (all P’s40.05) and consequently were not used as
covariates in subsequent behavioral analyses. As we did not
identify differences in demographics between participants
recruited at the three different sites (all P’s40.2), we did not
include scanning site as a covariate in behavioral analyses.
Task-related performance during evocative image processing
As shown in Table 1, participants in both the alcohol and alcohol/
drugs groups tended to respond more slowly in general, but there
was considerable variability and differences between the groups
failed to reach signiﬁcance (F2,57 = 3.04, P=0.056). There was a main
effect of condition (aversive versus neutral images; F1,57 = 11.27,
P=0.001), such that response latency to aversive images (818.87 ms
s.d. ± 343.55) was signiﬁcantly longer than response latency to
neutral images (758.11 ms ±271.47) (t59=− 3.36, P=0.001) across
groups. However, there was no main effect of treatment
(F1,57 = 0.006, P=0.941) and the group-by-treatment (F2,57 = 0.90,
P=0.915) and the group-by-treatment-by-condition (F2,57 = 0.45,
P=0.640) interactions were also not signiﬁcant.
Task-related brain activation during evocative image processing
Signiﬁcant correlations between the ROIs and childhood adversity
were found during the processing of aversive versus neutral
images as a function of pharmacological treatment. Figure 1a
Table 2. Group demographic information and baseline assessment prior to the experimental medicine sessions
Control group, n=21 Alcohol group, n= 18 Alcohol/drugs group, n= 21 Statistic, P-value
Site (London: Cambridge: Manchester) 8 L: 12 C: 1 M 9 L: 6 C: 3M 12 L: 7 C: 2 M X2= 4.04, P= 0.40
Gender (male: female) 17 M: 4 F 14 M: 4 F 16 M: 5 F X2= 0.15, P= 0.93
Age (years) 41.52 (±10.05) 44.22 (±8.72) 40.57 (±7.43) F2,57= 0.88, P= 0.42
Verbal IQ (WTAR) 106.57 (±10.88) 105.78 (±8.31) 99.57 (±11.45) F2,57= 2.80, P= 0.07
Handedness (Edinburgh Inventory) 40.62 (±67.71) 58.39 (±66.72) 61.33 (±58.06) F2,57= 0.63, P= 0.54
Smoking (smoker: non-smoker) 9 S: 12 N-S 13 S: 5 N-S 16 S: 5 N-S X2= 5.90, P= 0.052
Stress sensitivity (PSS-14, total score) 15.10 (±6.36) 18 (±7.23) 21.95 (±6.27) F2,57= 5.71, P= 0.005
Childhood adversity (CTQ total abuse score) 21.90 (±10.07) 22.61 (±12.06) 34.24 (±16.50) F2,57= 6.63, P= 0.003
Locus of control (Rotter’s I–E) 10.25 (±43.18) 10.76 (±43.39) 10.40 (±43.28) F2,57= 0.05, P= 0.95
Drug-related locus of control (DR-LOC recovery) 1.24 (±1.61) 1.50 (±1.58) 1.48 (± .98) F2,57= 0.21, P= 0.81
Abbreviations: CTQ, Childhood Trauma Questionnaire; DR-LOC, drug-related locus of control; PSS-14, Perceived Stress Scale; Rotter’s I–E, Rotter’s internal–
external control scale; WTAR, Wechsler Test of Adult Reading.
Figure 1. Naltrexone modulated (a) task-related activation in the right medial prefrontal cortex (mPFC; MNI coordinates: x,y,z: 20,60,0;
z-score= 3.71, P= 0.004) and (b) functional connectivity between the right anterior cingulate cortex (ACC; seed coordinates: x,y,z: − 14,62,1)
and the right hippocampus (MNI coordinates: x,y,z: 22,− 16, − 10; z-score= 3.11; P= 0.002) as a function of childhood adversity (Childhood
Trauma Questionnaire (CTQ) abuse score) in all groups.
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shows a positive association between activity in the right mPFC
(x,y,z: 20,60,0) and childhood adversity (z-score = 3.71, P= 0.004
FWE for multiple comparisons after small volume correction) and,
similarly, Figure 1b shows a positive association between
functional connectivity between the right ACC and the right
hippocampus (x,y,z: 22,− 16,− 10) and childhood adversity (z-
score = 3.11; P= 0.002, FWE for multiple comparisons after small
volume correction) in the placebo relative to the naltrexone
session. This pattern of association was found irrespective
of group.
As shown in Table 3, there was a main effect of group and a
main effect of condition in temporal–occipital regions. There was a
signiﬁcant group-by-treatment-by-condition interaction (z-score =
2.66; P= 0.032 FWE for multiple comparisons after small volume
correction) in the right amygdala (x,y,z: 26,2,− 24; Figure 2) while
viewing aversive and neutral images relative to baseline. Figure 2a
shows that the alcohol and control groups had higher activation in
the amygdala when processing aversive relative to neutral images
on placebo, thus demonstrating increased activation to threat-
related stimuli. However, activation in the amygdala increased to
both aversive and neutral images in the alcohol/drugs group,
irrespective of emotional valence.
Figure 2b shows that the group-by-treatment-by-condition
interaction was mainly driven by a normalization of response in
the amygdala for aversive relative to neutral images under
naltrexone in the alcohol/drugs group, whereas the pattern of
activation did not change in the alcohol and control groups. There
was no main effect of treatment and the group-by-treatment
interaction was not signiﬁcant.
DISCUSSION
Inﬂuence of childhood adversity on naltrexone
Childhood adversity was highly prevalent in our alcohol/drugs
group and signiﬁcantly differed between the patient groups. This
is in line with previous studies showing that individuals with a
history of childhood abuse are more prone to combined alcohol
and drug taking in adulthood.31–33 Sensitivity to stress was also
high in our alcohol/drugs group compared with the control group.
These differences support that aversive emotional states con-
tribute to negatively reinforced drug seeking, consistent with the
‘dark side’ view of addiction.8,9 Negative reinforcement thus acts
to increase more compulsive drug-seeking behavior, particularly
during the withdrawal/negative affect stage of the addiction
cycle.64
Similarities between the effects of childhood maltreatment, one
form of early adversity, and impairments in emotion regulation
systems underlying vulnerability to substance use disorders have
been identiﬁed, but are poorly understood.65 In maltreated
adolescents, increased activation in prefrontal regions has been
found during effortful control of emotion regulation.66 However,
surprisingly few fMRI studies have investigated brain response to
emotional stimuli in substance-dependent groups abused in
childhood. It has been shown that functional alterations in mPFC
activity are associated with greater maltreatment severity in
response to drug- and stress-related cues in individuals with
cocaine dependence.67 Heighted mesolimbic response has also
been found in response to drug-related and evocative cues in
cocaine-dependent individuals reporting a history of emotional,
physical and sexual abuse.68 Consistent with preclinical evidence
demonstrating that the therapeutic efﬁcacy of naltrexone is
associated with early adverse experiences,29 we found that
naltrexone modulated task-related activation in the mPFC, one
key region associated with emotion dysregulation in both
substance use disorders and adults with histories of childhood
adversity, depending on the degree of abuse experienced.
Naltrexone also modulated ACC–hippocampal connectivity, two
regions integral to mood regulation,69 depending on childhood
adversity. In fMRI studies, hippocampal activation and network
connectivity has been shown to predict cocaine relapse.12 Limbic
connectivity between the hippocampus and the amygdala is also
associated with reduced adaptive emotional processing in
maltreated individuals with methamphetamine dependence.11
Interplay between the ACC and the hippocampus has been
implicated in the reconsolidation and expression of fear
memories,70 with alterations in ACC–hippocampal connectivity
found in patients with posttraumatic stress disorder.71 These
ﬁndings, together with our data, suggests that opioid receptors in
the ACC and the hippocampus are important pharmacological
Table 3. Signiﬁcant whole-brain-corrected regions for the main effect
of group, main effect of condition and group-by-treatment-by-
condition interaction
Hemisphere P-value z-score Coordinates
(x:y:z)
Main effect of group
Fusiform gyrus Left 0.012 4.83 −26, − 66, − 16
Inferior occipital gyrus Left 0.025 4.66 − 26, − 82, − 6
Precuneus Right 0.029 4.63 30, − 60, 28
Main effect of condition
Inferior temporal gyrus Right 0.001 5.27 46, − 44, − 18
Superior temporal gyrus Left 0.023 4.66 − 58, − 12, 4
Middle occipital gyrus Left 0.028 4.61 − 44, − 80, − 2
Group-by-treatment-by-condition interaction
Amygdala Right 0.032 2.66 26, 2, −24
Figure 2. (a) Signiﬁcant group-by-treatment-by-condition interaction in the right amygdala (MNI coordinates: x,y,z: 26,2,− 24; z-score= 2.66;
P= 0.032). (b) On placebo, the control and alcohol groups showed increased activation to aversive relative to neutral images, whereas the
alcohol/drugs groups showed increased activation to all visual images, irrespective of emotional valence. (c) Naltrexone normalized activation
in the alcohol/drugs group, such that activation was higher to aversive relative to neutral images, but did not change the pattern of activation
in the control or alcohol groups. MNI, Montreal Neurological Institute.
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targets in individuals with a history of abuse, which, although not
speciﬁc to our substance-dependent groups, may be of relevance
to other disorders characterized by childhood adversity, such as
trauma-related or psychotic disorders.
The neurobiological effects of childhood adversity on emotional
processing are under-investigated in addiction. Our data conﬁrm
that environmental factors, speciﬁcally early adverse experiences,
inﬂuence variations in naltrexone response. It is possible that
differences in childhood adversity might account for some of the
variability in outcome in alcohol-dependent patients treated with
naltrexone. Early life experiences have been shown to affect the
endogenous opioid system in preclinical models,72,73 and the
present data offer convergent evidence that the effects of
childhood adversity on endogenous opioids are an important
indicator of responsiveness to pharmacological treatments acting
on MOR transmission in humans. We suggest that behavioral
interventions that promote emotion regulation strategies for
traumatic experiences or pharmacological interventions that
normalize cortical–limbic connectivity may be effective in groups
with high levels of childhood adversity.
Effects of MOR blockade on different types of substance
dependence
Previous fMRI studies have shown altered limbic activation in
response to naturally evocative,16 negative emotional37,38 and
substance-related74–78 stimuli in substance-dependent groups. We
observed greater task-related activation in the right amygdala
during the processing of aversive relative to neutral images under
placebo in individuals recovering from alcohol dependence.
Heightened reactivity in this region is consistent with previous
investigations measuring brain response to negative IAPS images
in individuals with alcohol dependence.38 Similar to our alcohol
group, participants from the above studies were characterized by
only one drug dependency. The lack of discriminatory response
between aversive and neutral images was speciﬁc to our alcohol/
drugs group, possibly reﬂecting an emotional desensitization
following prior exposure to adverse events, an attentional
disengagement to aversive images (although we consider this
unlikely as our task does not tap into attentional resources) or
altered MOR availability/density associated with abstinence from
repeated drug exposure (for example, cocaine;79,80 opiates;81
alcohol82,83) and/or individual differences in environment factors.
Although speculative for the present study, these possibilities
each deserve more detailed investigation in substance-dependent
groups, including use of positron emission tomography to
elucidate whether associations between MOR binding potential
and limbic activation differ during negative emotional processing
between alcohol-dependent patients with and without combined
drug dependence.
Our data further showed that naltrexone normalized the pattern
of activation in the amygdala for aversive relative to neutral
images in our alcohol/drugs group (that is, there was only an
effect of treatment at the group level when interacting with the
content of the images presented). These data demonstrate that
naltrexone-induced functional alterations during negative emo-
tional processing are speciﬁc to groups characterized by distinct
patterns of drug dependencies that can persist in prolonged
abstinence. Activation of stress-induced neurocircuitry contributes
to the ‘dark side’ view of addiction, in which recruitment of brain
‘anti-reward’ systems (for example, within motivational circuits of
the extended amygdala), an opponent process to hyperactivation
of the brain reward system, provides strong motivation for
negatively reinforced drug seeking.64,84 Increased activation in
response to aversive images could also lend vulnerability to
craving and relapse via stress-induced reinstatement of emotion-
processing circuitry.8,9,84 However, a relative normalization of
response by naltrexone in our alcohol/drugs group is likely due to
a kappa-antagonist effect being more potent in individuals with
increased dynorphin-dependent KOR activation. The latter is
associated with negative emotional states, higher sensitivity to
stress and/or more severe psychopathology as a consequence of
combined drug taking.85 Stress-induced activation of the dynor-
phin/kappa-opioid system has dysphoric-like effects that are
thought to mediate negative emotional states.86,87 However,
KOR blockade has shown consistent anxiolytic and antidepressant
effects in both humans and animals, including attenuation of a
stress response.88,89 Evaluation of the potential therapeutic
beneﬁts of selective kappa-opioid antagonism in the treatment
of addiction and comorbid stress-related mood disorders thus
may form an important area of new research. Increasing activation
of the HPA axis with mu-opioid antagonism (including adreno-
corticotropic hormone, beta-endorphin and cortisol levels) is also
a potential mechanism for reducing craving and withdrawal
symptoms in alcohol addiction.
Treatment implications
Naltrexone signiﬁcantly reduces return to heavy drinking (to 83%
of the risk of placebo) and decreases drinking days by about 4%.90
In individuals with opioid dependence, the efﬁcacy of naltrexone
treatment is largely heterogeneous and most effective in
subgroups that complete treatment.91 However, medication
compliance and retention rates remain poor (28%), particularly
during early stages of recovery.92 This is likely explained by
unwanted side effects such as sedation (for example, daytime
sleepiness) and gastrointestinal problems (for example, nausea,
stomach pain, loss of appetite).90 Extended-release naltrexone has
thus been developed and used, with success, to improve
adherence over and above other pharmacotherapies used in the
treatment of alcohol and opioid dependence (for example,
acamprosate, buprenorphine).93
Encouragingly, cognitive behavioral therapy with adjunct
naltrexone treatment has shown to reduce return to drinking in
alcohol-dependent adults, thus suggesting beneﬁcial, synergistic
effects of concurrent therapies.94 Cognitive behavioral therapy
also has the potential to improve functional abnormalities during
emotional processing (in the medial prefrontal and anterior
cingulate cortices, for example), as shown in patients with
depression.95,96 Interventions that combine naltrexone and coping
skills have shown to improve treatment outcome in alcohol and
cocaine dependence.97–99 Coping skills therapies with a particular
focus on relapse prevention may also help naltrexone-treated
patients better manage their emotions after non-substance using
strategies are implemented. As the current treatment length of
naltrexone is recommended for 6 months,17 coping skills for
childhood adversity should be addressed and evaluated as part of
a longer-term therapeutic process for addiction recovery.
Limitations
The main limitation of our analyses is its use of a retrospective self-
report measure of childhood adversity. Measurement of an
emotional or traumatic event may be unreliable as recollection
is likely to be inﬂuenced by several confounding factors including
memory biases, memory repression and current mood; however,
retrospective recall of physical and sexual abuse is associated with
more false negatives than false positives,100 suggesting a greater
tendency for adults to under- rather than to overestimate the
occurrence of an abusive experience.
Secondly, our study only investigated the effects of naltrexone
on the processing of aversive images compared with neutral
images. Comparison with positive or rewarding non-alcohol and
-drug-related images would have allowed us to investigate if the
valence of emotional processing had a differential treatment
effect, or if motivational salience had the same effect irrespective
of emotionality.
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Lastly, childhood adversity is a robust risk factor for other
disorders in which emotional problems pervade. Major depressive
disorder, for example, is associated with abnormal responses to
negative emotional stimuli in similar brain regions observed
here.95,96 It is possible that variations in anxiety and depression
could also drive abnormalities in negative emotional processing in
substance use disorders, or that more severe comorbidity has a
particularly potent effect for enhancing emotion-processing
circuitry. Although we cannot preclude this possibility from the
current data, levels of anxiety and depression were consistent in
groups across the experimental medicine sessions (and therefore
exerting the same inﬂuence on emotional processing at both time
points), and sensitivity to stress did not differ between the patient
groups at baseline.
CONCLUSIONS
Problems with emotion regulation may predate substance
dependence, or may serve to exacerbate susceptibility to relapse
during addiction recovery. Furthermore, loss of brain reward and
recruitment of brain stress systems produces negatively reinforced
motivation for compulsive drug seeking and addiction. The
present study demonstrates that the effects of naltrexone on
cortical activation and cortical–limbic connectivity are dependent
on variations in childhood adversity (that is, the more abuse
experienced, the greater the ameliorative effect of naltrexone).
Pharmacotherapy with naltrexone may also have some ameliora-
tive effects on negative emotional processing in the amygdala in
individuals with combined alcohol and drug dependence, but not
alcohol dependence alone, possibly because of alterations in
endogenous opioid transmission or the KOR antagonist actions of
naltrexone. Childhood adversity was higher in individuals with
combined alcohol and drug dependence compared with indivi-
duals dependent on alcohol only and should thus be an important
consideration by treatment strategies for addiction. We conclude
that childhood adversity is one environmental factor that
inﬂuences pharmacological response to naltrexone. More tailored
treatment approaches are required that take into account such
early experiential factors.
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